Most men should start talking to their doctor about prostate cancer screening at age 50, but if you’re Black or have a family history of prostate cancer, that conversation should happen earlier, around age 40 to 45. The right age depends on your personal risk factors, and there’s no single rule that applies to everyone.
Screening Ages by Risk Level
The American Cancer Society breaks it down into three groups. Men at average risk should have the screening conversation at age 50. Men at high risk, meaning Black men or those with a father or brother diagnosed with prostate cancer before age 65, should start at 45. Men at even higher risk, specifically those with more than one close relative diagnosed at a young age, should start at 40.
The U.S. Preventive Services Task Force takes a slightly different angle. It frames the strongest case for screening as the 55 to 69 age window, where the potential benefits are most likely to outweigh the harms. For men 70 and older, the task force recommends against routine screening entirely, since the slow-growing nature of most prostate cancers means they’re unlikely to cause problems within a typical remaining lifespan.
Both organizations emphasize one common thread: screening is a personal decision, not an automatic checkbox. The goal is to have an informed conversation with your doctor before any test is ordered.
Why Black Men Should Start Earlier
Prostate cancer develops three to nine years earlier in Black men compared to non-Black men, and Black men in the United States face the highest risk of both diagnosis and death from the disease. Guidelines from the Prostate Cancer Foundation recommend that Black men begin discussing screening in their early 40s, with a baseline blood test (called a PSA test) between ages 40 and 45. This isn’t a minor adjustment. It reflects a meaningfully different disease timeline that standard age-50 recommendations don’t account for.
Genetic Mutations That Change the Timeline
If you carry certain inherited gene mutations, particularly in the BRCA1 or BRCA2 genes (the same ones linked to breast and ovarian cancer risk in women), multiple expert panels recommend starting screening at age 40. For BRCA2 carriers, the recommendation is especially strong, while for BRCA1 carriers the language is softer (“consider” rather than “recommend”). Another useful rule of thumb: start screening 10 years before the youngest prostate cancer diagnosis in your family. So if your father was diagnosed at 52, you’d want to begin at 42.
What the Screening Actually Involves
Prostate cancer screening today is primarily a blood test. The PSA test measures a protein produced by the prostate, and levels above about 4.0 ng/mL are generally considered abnormal. Some doctors use lower cutoffs (around 2.5 ng/mL) for younger men and higher cutoffs for older men, since PSA naturally rises with age.
You may be wondering about the digital rectal exam, where a doctor physically feels the prostate through the rectum. For years it was considered a standard part of screening, but the evidence now shows it performs poorly as a standalone screening tool and doesn’t meaningfully improve detection when added to a PSA test. Current UK guidance, for example, skips the rectal exam in initial screening and goes straight to MRI if the PSA is elevated. A rectal exam may still be useful if your PSA is normal but your doctor has other reasons for concern, such as symptoms or high-risk factors, but it’s no longer a routine part of screening for most men.
How Often to Get Screened
Once you start screening, the frequency depends on your initial PSA result. The American Cancer Society recommends rescreening every two years if your PSA is at or above 2.5 ng/mL, and every one to two years may be appropriate depending on how quickly the number is rising. If your PSA is below 2.5 ng/mL, screening every two years is generally sufficient, and some guidelines suggest you can stretch to longer intervals if the level is very low. Your doctor will adjust this schedule based on your results and risk profile.
When to Stop Screening
The general principle is that screening stops making sense when your life expectancy is less than 10 years, regardless of age. Prostate cancer typically grows slowly, so detecting it late in life often leads to treatment that causes more harm (incontinence, sexual side effects) than the cancer itself would have. The task force draws a firm line at age 70 for routine screening, though the American Cancer Society and the American Urological Association prefer the life-expectancy approach rather than a hard age cutoff. If you’re in your mid-70s and in excellent health, the decision is worth discussing with your doctor rather than assuming screening is off the table.
Symptoms That Warrant an Exam at Any Age
Screening guidelines apply to men without symptoms. If you’re experiencing certain warning signs, age becomes irrelevant. Blood in your urine is the most urgent signal. Even if it happens once and there’s no pain, it needs evaluation. Other symptoms that should prompt a visit include difficulty urinating or fully emptying your bladder, a noticeably weak urine stream, frequent urination (especially waking multiple times at night), pelvic pain, blood in semen, or new erectile dysfunction.
These symptoms don’t necessarily mean cancer. An enlarged prostate, infections, and other benign conditions cause similar problems. But they all deserve a workup, and your doctor will likely order a PSA test as part of that evaluation.
What Happens If Your PSA Is High
A high PSA result doesn’t mean you have cancer. PSA can be elevated by infections, an enlarged prostate, recent vigorous exercise, or even ejaculation within the previous day or two. If your first result is elevated, your doctor will typically repeat the test to confirm. If the level stays high or is rising quickly, the next step is usually an MRI of the prostate, which can identify suspicious areas without any needles. If the MRI shows something concerning, a targeted biopsy follows. This modern approach, MRI first and then biopsy only if needed, has significantly reduced unnecessary biopsies compared to older protocols where an elevated PSA alone triggered an immediate biopsy.